Non-Invasive Monitoring Systems Inc. (NIMU)

[Special Situations]

NIMU + Upd. Info.

* * *

NIMU
Non-Invasive Monitoring Systems, Inc.



#Share Structure.
A/S: 400,000,000
O/S: 154,810,655
Restricted O/S: 111,593,393
Unrestricted O/S: 43,217,262
Held at DTC: 39,948,758

https://www.otcmarkets.com/stock/NIMU/security



#Reporting Status.
U.S. Reporting: SEC Reporting



#Florida SOS.
Incorporated In: Florida
Florida SOS Status: INACTIVE

http://search.sunbiz.org/Inquiry/CorporationSearch/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=NONINVASIVEMONITORINGSYSTEMS%206817062&aggregateId=domp-681706-93eecf7a-c32f-487c-b9b9-de40ae365acc&searchTerm=Non-Invasive%20Monitoring%20Systems&listNameOrder=NONINVASIVEMONITORINGSYSTEMS%206817062



#Plan of Operation.
"The Company is currently a shell company (as defined in Rule 12b-2 of the Exchange Act)."
"The Company is assessing potential mergers, acquisitions and strategic collaborations."
"The Company is seeking potential mergers, acquisitions and strategic collaborations."

Form 10-Q (for the Quarterly Period ended October 31, 2020).
https://www.sec.gov/Archives/edgar/data/720762/000149315220023536/form10-q.htm



#NOL.
"At July 31, 2020, the Company had available Federal and State net operating loss carry forwards of approximately $16.9 million and foreign net operating loss carry forwards of approximately $0.1 million which expire in various years beginning in 2020."

Form 10-K (For the fiscal year ended July 31, 2020).
https://www.sec.gov/Archives/edgar/data/720762/000149315220020128/form10-k.htm



#Insider Ownership.

Dr. Phillip Frost
Common Stock: 54,690,325
Common Stock (%): 35.3%

Dr. Phillip Frost (Forbes).
https://www.forbes.com/profile/phillip-frost/

Dr. Phillip Frost (Bloomberg).
https://www.bloomberg.com/profile/person/1423894

Dr. Phillip Frost (Wikipedia).
https://en.wikipedia.org/wiki/Phillip_Frost




Jane H. Hsiao
Common Stock: 43,455,734
Common Stock (%): 28.1%

"Jane H. Hsiao, Ph.D., MBA. Dr. Hsiao has served as a Director and Chairman of the Board of Directors (the “Board”) of the Company since October 2008 and as Interim Chief Executive Officer since February 2012. Dr. Hsiao has served as Vice Chairman and Chief Technical Officer of OPKO Health, Inc. (NASDAQ GS:OPK), a specialty healthcare company, since May 2007 and as a director since February 2007. Dr. Hsiao is also a director of each of TransEnterix, Inc. (NYSE: TRXC), a medical device company. Dr. Hsiao previously served as a director of Cocrystal Pharma, Inc. (NASDAQ GM:COCP), a biotechnology company developing antiviral therapeutics for human diseases, Neovasc, Inc. (NASDAQ CM:NVCN), a company developing and marketing medical specialty vascular devices. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX’s veterinary products subsidiary, from 1998 to 2006."
Form 10-K (For the fiscal year ended July 31, 2020).
https://www.sec.gov/Archives/edgar/data/720762/000149315220020128/form10-k.htm


Jane H. Hsiao (Forbes).
https://www.forbes.com/profile/jane-hsiao/

Jane H. Hsiao (Bloomberg).
https://www.bloomberg.com/profile/person/1455827



* * *